07:00 , Sep 15, 2014 |  BioCentury  |  Product Development

Ebola realities

Hope that experimental Ebola vaccines and therapies might help contain the current outbreak is sliding into hype as public health officials exaggerate how quickly new products could be deployed and minimize the uncertainties inherent in...
07:00 , Aug 11, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) was up $0.44 to $22.47 last week after submitting a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. AIGIV is being developed under...
07:00 , Jul 26, 2010 |  BC Week In Review  |  Clinical News

NanoViricides preclinical data

In cell culture screening assays, several anti-Ebola virus nanoviricides dose-dependently inhibited Ebola virus infectivity with no toxicity of uninfected cells. In a mouse model of Ebola infection, treatment with the nanoviricides led to a 30-40%...